Year: 2022

Global Sulfuric Acid Market Set to Generate Revenue of $13.44 Billion by 2028 | 54% of Global Sulfuric Acid is Used for Manufacturing of Chemical Fertilizers

Written by Customer Service on November 11, 2022. Posted in Mergers And Acquisitions.

Global sulfuric acid market was valued at USD 11 billion in 2021, and it is expected to attain a value of USD 13.44 billion by 2028, at a CAGR of 2.91% over the prediction period (2022 – 2028). Westford, USA, Nov. 11, 2022 (GLOBE NEWSWIRE) — Sulfuric acid is a key ingredient in the production of fertilizers, and with the world’s population expected to continue to grow, the demand for this vital commodity is only set to increase. The majority of the product in the global sulfuric acid market is produced via the contact process, which involves burning sulfur in air to produce sulfur dioxide, which is then converted into sulfuric acid in the presence of an oxidizing agent. With global demand for fertilizer expected to increase in coming years, companies involved in the production of sulfuric acid are well positioned to benefit...

Verizon to speak at NSR & BCG conference November 14

Written by Customer Service on November 11, 2022. Posted in Public Companies.

NEW YORK, Nov. 11, 2022 (GLOBE NEWSWIRE) — Sowmyanarayan Sampath, executive vice president for Verizon (NYSE, Nasdaq: VZ), and CEO for Verizon Business, is scheduled to speak at the NSR & BCG Innovation Conference on Monday, November 14, at 10:30 a.m. ET. His remarks will be webcast, with access instructions available on Verizon’s Investor Relations website, www.verizon.com/about/investors. Verizon Communications Inc. (NYSE, Nasdaq: VZ) was formed on June 30, 2000 and is one of the world’s leading providers of technology and communications services. Headquartered in New York City and with a presence around the world, Verizon generated revenues of $133.6 billion in 2021. The company offers data, video and voice services and solutions on its award-winning networks and platforms, delivering on customers’ demand for mobility,...

AAR earns 2023 Military Friendly® Employer designations

Written by Customer Service on November 11, 2022. Posted in Public Companies.

Military Friendly® Spouse Employer logo AAR CORP. earns Military Friendly® Spouse Employer designationMilitary Friendly® Gold Employer logo AAR CORP. earns Military Friendly® Employer Gold designationWood Dale, Illinois, Nov. 11, 2022 (GLOBE NEWSWIRE) — AAR CORP. (NYSE: AIR), a leading provider of aviation services to commercial and government operators, MROs, and OEMs, announced today that it earned the 2023 Military Friendly® Employer Gold designation and 2023 Military Friendly® Spouse Employer designation. Institutions earning the Military Friendly® Employer designations were evaluated using both public data sources and responses from a proprietary survey. Over a thousand companies participated in the 2023 Military Friendly® survey. Methodology, criteria, and weightings were determined by VIQTORY with input from the Military...

Apexigen Announces New Data from a Phase 1/2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with First-Line Metastatic Melanoma at the SITC 2022 Annual Meeting

Written by Customer Service on November 11, 2022. Posted in Public Companies.

– The combination of intratumoral sotigalimab and systemic pembrolizumab was well-tolerated and demonstrated an improved clinical response rate relative to the standard of care, pembrolizumab monotherapy- -Activation of antigen-presenting cells stimulated broad innate and adaptive anti-tumor responses in both local as well as distant tumor lesions- SAN CARLOS, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) — Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced new data from an ongoing Phase 2 investigator-sponsored trial evaluating intratumoral sotigalimab (sotiga), Apexigen’s CD40 agonist antibody, in combination with systemic pembrolizumab (anti-PD-1 antibody) in first-line metastatic melanoma....

Arcutis to Present at Upcoming Investor Conference

Written by Customer Service on November 11, 2022. Posted in Public Companies.

WESTLAKE VILLAGE, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in an upcoming investor conference. Details for the company’s participation are as follows:Guggenheim 4th Annual Immunology and Neurology DayFireside Chat Date: Tuesday, November 15, 2022Fireside Chat Time: 10:45 a.m. ETThe webcast for this conference may be accessed at the “Events” section of the Company’s website. The replay of the webcast will be available on the Arcutis website for 30 days following the conference. About ArcutisArcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent...

Immix Biopharma Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical Trial, Key Requirement for U.S. Food and Drug Administration Approval of Rare Pediatric Disease Priority Review Voucher

Written by Customer Service on November 11, 2022. Posted in Public Companies.

Immix Biopharma Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical Trial, Key Requirement for U.S. Food and Drug Administration Approval of Rare Pediatric Disease Priority Review Voucher Immix Biopharma, Inc. (NASDAQ:IMMX)Enrolling pediatric patients in a clinical trial is a key requirement for FDA approval of a Priority Review Voucher (“PRV”) While their future value is uncertain, PRVs are transferable to other companies and have historically sold for $67 to $350 million according to a January 2020 report on drug development by the Government Accountability OfficeA photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/be19ab99-a0c8-4850-a0a4-1592fdc18600 LOS ANGELES, Nov. 11, 2022 (GLOBE NEWSWIRE) — Immix Biopharma, Inc....

Nemaura Medical to Present at the Bernstein 2ND Annual CGM Disruptors Conference

Written by Customer Service on November 11, 2022. Posted in Public Companies.

Loughborough, England, Nov. 11, 2022 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present a corporate overview at at the Bernstein 2nd Annual CGM Disruptors Conference which is being held virtually on November 18, 2022.Event: Bernstein 2ND Annual CGM Disruptors ConferencePresentation Date: November 18, 2022Time: 10:30am ET About Nemaura Medical, Inc. Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb...

Crown Electrokinetics Corp. Reports Third Quarter 2022 Financial Results

Written by Customer Service on November 11, 2022. Posted in Earnings Releases And Operating Results.

LOS ANGELES, Nov. 11, 2022 (GLOBE NEWSWIRE) — Crown Electrokinetics Corp. (NASDAQ: CRKN) (“Crown” or the “Company”), a leading smart glass technology company, will report its financial results for the Third Quarter 2022 today, Friday, November 11, 2022. Doug Croxall, Crown CEO and Chairman, “We are pleased to recently have capitalized the Company in a difficult macro environment. This new capital will allow Crown to deliver its first-generation product, while also providing us with the runway to continue negotiating debt capital, which the Company will require to initiate our next phase of manufacturing. We remain active in those discussions which once completed, would allow us to build our new roll-to-roll lines enabling us to produce film at widths ranging between 12 inches and 72 inches.” Corporate Updates During and Subsequent...

Century Announces Filing of Second Quarter Financial Results and Management Discussion and Analysis for Six Months Ended September 30, 2022

Written by Customer Service on November 11, 2022. Posted in Earnings Releases And Operating Results.

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION INTHE UNITED STATES OR TO U.S. NEWS AGENCIES HONG KONG, Nov. 11, 2022 (GLOBE NEWSWIRE) — Century Global Commodities Corporation (“Century” or the “Company”) (TSX: CNT) is pleased to announce that it has filed its condensed consolidated interim financial statements for the second fiscal quarter ended September 30, 2022 and the related management discussion and analysis (“MD&A”). Copies of these documents are available under Century’s SEDAR profile at www.sedar.com and will also be posted on Century’s website at www.centuryglobal.ca. As of September 30, 2022, the Company had strong net working capital∗ of $9.9 million, consisting of cash, bank deposits and marketable securities totaling $7.4 million, together with accounts receivables and other current assets of $5.0 million, less accounts...

Mattress Market to Exceed Sales Revenue of $72.10 Billion by 2028 | Consumers are Slowing Spending More to Get Better Good Night Sleep

Written by Customer Service on November 11, 2022. Posted in Mergers And Acquisitions.

Global mattress market was valued at USD 45.2 billion in 2021, and it is expected to reach a value of USD 72.10 billion by 2028, at a CAGR of more than 6.9% over the forecast period (2022–2028). Westford, USA, Nov. 11, 2022 (GLOBE NEWSWIRE) — As the world progresses, so does the way we sleep. In the past, people would sleep on anything from hay to feathers. But now, as comfort is increasingly valued, the mattress industry is booming. With good reason – a comfortable mattress can make all the difference to a good night’s sleep. There are many different types of mattresses available on the global mattress market, from memory foam to latex to spring. With so many options available, it’s no wonder that the demand for mattresses is growing. As per SkyQuest analysis, memory foam mattresses are perhaps the most popular type on the market...

Year: 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals